Global Gastroesophageal Reflux Disease (Gerd) Market 2024-2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	176 Pages	TechNavio	May, 2024	INF18930272

Best Price Guarantee
Price	from $2,500
Length	176 Pages
Publisher	TechNavio
Published Date	May, 2024
SKU	INF18930272

Global Gastroesophageal Reflux Disease (GERD) Market 2024-2028

Technavio has been monitoring the gastroesophageal reflux disease (GERD) market and is forecast to grow by USD 879.8 mn during 2023-2028, accelerating at a CAGR of 3.2% during the forecast period. Our report on the gastroesophageal reflux disease (GERD) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising geriatric population, poor lifestyle patterns, and overuse of medicines and dietary supplements.

Technavio's gastroesophageal reflux disease (GERD) market is segmented as below:

By Route Of Administration

Oral
Parenteral

By Type

Antacid
PPI
H2 receptor antagonist drugs
Pro-Kinetic drugs

By Geography

North America
Europe
Asia
Rest of World (ROW)

This study identifies the rising prevalence of obesity as one of the prime reasons driving the gastroesophageal reflux disease (GERD) market growth during the next few years. Also, growing e-commerce market and increasing awareness of GERD will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the gastroesophageal reflux disease (GERD) market covers the following areas:

Gastroesophageal reflux disease (GERD) market sizing
Gastroesophageal reflux disease (GERD) market forecast
Gastroesophageal reflux disease (GERD) market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gastroesophageal reflux disease (GERD) market vendors that include Abbott Laboratories, Alkem Laboratories Ltd., Apotex Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bayer AG, Cipla Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, inovapharma.com, Johnson and Johnson Services Inc., Lupin Ltd., Perrigo Co. Plc, Pfizer Inc., SRS Life Sciences Pte. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and The Procter and Gamble Co.. Also, the gastroesophageal reflux disease (GERD) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

1 Executive Summary: 1.1 Market overview; Executive Summary - Chart on Market Overview; Executive Summary - Data Table on Market Overview; Executive Summary - Chart on Global Market Characteristics; Executive Summary - Chart on Market by Geography; Executive Summary - Chart on Market Segmentation by Route of Administration; Executive Summary - Chart on Market Segmentation by Type; Executive Summary - Chart on Incremental Growth; Executive Summary - Data Table on Incremental Growth; Executive Summary - Chart on Company Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Parent Market; Data Table on - Parent Market; 2.2 Market characteristics; Market characteristics analysis; 2.3 Value chain analysis; Value Chain Analysis
3 Market Sizing: 3.1 Market definition; Offerings of companies included in the market definition; 3.2 Market segment analysis; Market segments; 3.3 Market size 2023; 3.4 Market outlook: Forecast for 2023-2028; Chart on Global - Market size and forecast 2023-2028 ($ million); Data Table on Global - Market size and forecast 2023-2028 ($ million); Chart on Global Market: Year-over-year growth 2023-2028 (%); Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size: 4.1 Global Gastroesophageal Reflux Disease (GERD) Market 2018 - 2022; Historic Market Size - Data Table on Global Gastroesophageal Reflux Disease (GERD) Market 2018 - 2022 ($ million); 4.2 Route of Administration segment analysis 2018 - 2022; Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million); 4.3 Type segment analysis 2018 - 2022; Historic Market Size - Type Segment 2018 - 2022 ($ million); 4.4 Geography segment analysis 2018 - 2022; Historic Market Size - Geography Segment 2018 - 2022 ($ million); 4.5 Country segment analysis 2018 - 2022; Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis: 5.1 Five forces summary; Five forces analysis - Comparison between 2023 and 2028; 5.2 Bargaining power of buyers; Bargaining power of buyers - Impact of key factors 2023 and 2028; 5.3 Bargaining power of suppliers; Bargaining power of suppliers - Impact of key factors in 2023 and 2028; 5.4 Threat of new entrants; Threat of new entrants - Impact of key factors in 2023 and 2028; 5.5 Threat of substitutes; Threat of substitutes - Impact of key factors in 2023 and 2028; 5.6 Threat of rivalry; Threat of rivalry - Impact of key factors in 2023 and 2028; 5.7 Market condition; Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Route of Administration: 6.1 Market segments; Chart on Route of Administration - Market share 2023-2028 (%); Data Table on Route of Administration - Market share 2023-2028 (%); 6.2 Comparison by Route of Administration; Chart on Comparison by Route of Administration; Data Table on Comparison by Route of Administration; 6.3 Oral - Market size and forecast 2023-2028; Chart on Oral - Market size and forecast 2023-2028 ($ million); Data Table on Oral - Market size and forecast 2023-2028 ($ million); Chart on Oral - Year-over-year growth 2023-2028 (%); Data Table on Oral - Year-over-year growth 2023-2028 (%); 6.4 Parenteral - Market size and forecast 2023-2028; Chart on Parenteral - Market size and forecast 2023-2028 ($ million); Data Table on Parenteral - Market size and forecast 2023-2028 ($ million); Chart on Parenteral - Year-over-year growth 2023-2028 (%); Data Table on Parenteral - Year-over-year growth 2023-2028 (%); 6.5 Market opportunity by Route of Administration; Market opportunity by Route of Administration ($ million); Data Table on Market opportunity by Route of Administration ($ million)
7 Market Segmentation by Type: 7.1 Market segments; Chart on Type - Market share 2023-2028 (%); Data Table on Type - Market share 2023-2028 (%); 7.2 Comparison by Type; Chart on Comparison by Type; Data Table on Comparison by Type; 7.3 Antacid - Market size and forecast 2023-2028; Chart on Antacid - Market size and forecast 2023-2028 ($ million); Data Table on Antacid - Market size and forecast 2023-2028 ($ million); Chart on Antacid - Year-over-year growth 2023-2028 (%); Data Table on Antacid - Year-over-year growth 2023-2028 (%); 7.4 PPI - Market size and forecast 2023-2028; Chart on PPI - Market size and forecast 2023-2028 ($ million); Data Table on PPI - Market size and forecast 2023-2028 ($ million); Chart on PPI - Year-over-year growth 2023-2028 (%); Data Table on PPI - Year-over-year growth 2023-2028 (%); 7.5 H2 receptor antagonist drugs - Market size and forecast 2023-2028; Chart on H2 receptor antagonist drugs - Market size and forecast 2023-2028 ($ million); Data Table on H2 receptor antagonist drugs - Market size and forecast 2023-2028 ($ million); Chart on H2 receptor antagonist drugs - Year-over-year growth 2023-2028 (%); Data Table on H2 receptor antagonist drugs - Year-over-year growth 2023-2028 (%); 7.6 Prokinetic drugs - Market size and forecast 2023-2028; Chart on Prokinetic drugs - Market size and forecast 2023-2028 ($ million); Data Table on Prokinetic drugs - Market size and forecast 2023-2028 ($ million); Chart on Prokinetic drugs - Year-over-year growth 2023-2028 (%); Data Table on Prokinetic drugs - Year-over-year growth 2023-2028 (%); 7.7 Market opportunity by Type; Market opportunity by Type ($ million); Data Table on Market opportunity by Type ($ million)
8 Customer Landscape: 8.1 Customer landscape overview; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape: 9.1 Geographic segmentation; Chart on Market share By Geographical Landscape2023-2028 (%); Data Table on Market share By Geographical Landscape2023-2028 (%); 9.2 Geographic comparison; Chart on Geographic comparison; Data Table on Geographic comparison; 9.3 North America - Market size and forecast 2023-2028; Chart on North America - Market size and forecast 2023-2028 ($ million); Data Table on North America - Market size and forecast 2023-2028 ($ million); Chart on North America - Year-over-year growth 2023-2028 (%); Data Table on North America - Year-over-year growth 2023-2028 (%); 9.4 Europe - Market size and forecast 2023-2028; Chart on Europe - Market size and forecast 2023-2028 ($ million); Data Table on Europe - Market size and forecast 2023-2028 ($ million); Chart on Europe - Year-over-year growth 2023-2028 (%); Data Table on Europe - Year-over-year growth 2023-2028 (%); 9.5 Asia - Market size and forecast 2023-2028; Chart on Asia - Market size and forecast 2023-2028 ($ million); Data Table on Asia - Market size and forecast 2023-2028 ($ million); Chart on Asia - Year-over-year growth 2023-2028 (%); Data Table on Asia - Year-over-year growth 2023-2028 (%); 9.6 Rest of World (ROW) - Market size and forecast 2023-2028; Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); 9.7 US - Market size and forecast 2023-2028; Chart on US - Market size and forecast 2023-2028 ($ million); Data Table on US - Market size and forecast 2023-2028 ($ million); Chart on US - Year-over-year growth 2023-2028 (%); Data Table on US - Year-over-year growth 2023-2028 (%); 9.8 Germany - Market size and forecast 2023-2028; Chart on Germany - Market size and forecast 2023-2028 ($ million); Data Table on Germany - Market size and forecast 2023-2028 ($ million); Chart on Germany - Year-over-year growth 2023-2028 (%); Data Table on Germany - Year-over-year growth 2023-2028 (%); 9.9 UK - Market size and forecast 2023-2028; Chart on UK - Market size and forecast 2023-2028 ($ million); Data Table on UK - Market size and forecast 2023-2028 ($ million); Chart on UK - Year-over-year growth 2023-2028 (%); Data Table on UK - Year-over-year growth 2023-2028 (%); 9.10 China - Market size and forecast 2023-2028; Chart on China - Market size and forecast 2023-2028 ($ million); Data Table on China - Market size and forecast 2023-2028 ($ million); Chart on China - Year-over-year growth 2023-2028 (%); Data Table on China - Year-over-year growth 2023-2028 (%); 9.11 Canada - Market size and forecast 2023-2028; Chart on Canada - Market size and forecast 2023-2028 ($ million); Data Table on Canada - Market size and forecast 2023-2028 ($ million); Chart on Canada - Year-over-year growth 2023-2028 (%); Data Table on Canada - Year-over-year growth 2023-2028 (%); 9.12 Market opportunity by geography; Market opportunity By Geographical Landscape($ million); Data Tables on Market opportunity By Geographical Landscape($ million)
10 Drivers, Challenges, and Opportunity/Restraints: 10.1 Market drivers; 10.2 Market challenges; 10.3 Impact of drivers and challenges; Impact of drivers and challenges in 2023 and 2028; 10.4 Market opportunities/restraints
11 Competitive Landscape: 11.1 Overview; 11.2 Competitive Landscape; Overview on criticality of inputs and factors of differentiation; 11.3 Landscape disruption; Overview on factors of disruption; 11.4 Industry risks; Impact of key risks on business
12 Competitive Analysis: 12.1 Companies profiled; Companies covered; 12.2 Market positioning of companies; Matrix on companies position and classification; 12.3 Abbott Laboratories; Abbott Laboratories - Overview; Abbott Laboratories - Business segments; Abbott Laboratories - Key news; Abbott Laboratories - Key offerings; Abbott Laboratories - Segment focus; 12.4 Alkem Laboratories Ltd.; Alkem Laboratories Ltd. - Overview; Alkem Laboratories Ltd. - Business segments; Alkem Laboratories Ltd. - Key offerings; Alkem Laboratories Ltd. - Segment focus; 12.5 Apotex Inc.; Apotex Inc. - Overview; Apotex Inc. - Product / Service; Apotex Inc. - Key news; Apotex Inc. - Key offerings; 12.6 AstraZeneca Plc; AstraZeneca Plc - Overview; AstraZeneca Plc - Product / Service; AstraZeneca Plc - Key news; AstraZeneca Plc - Key offerings; 12.7 Aurobindo Pharma Ltd.; Aurobindo Pharma Ltd. - Overview; Aurobindo Pharma Ltd. - Product / Service; Aurobindo Pharma Ltd. - Key offerings; 12.8 Bayer AG; Bayer AG - Overview; Bayer AG - Business segments; Bayer AG - Key news; Bayer AG - Key offerings; Bayer AG - Segment focus; 12.9 Cipla Inc.; Cipla Inc. - Overview; Cipla Inc. - Business segments; Cipla Inc. - Key news; Cipla Inc. - Key offerings; Cipla Inc. - Segment focus; 12.10 Dr Reddys Laboratories Ltd.; Dr Reddys Laboratories Ltd. - Overview; Dr Reddys Laboratories Ltd. - Business segments; Dr Reddys Laboratories Ltd. - Key news; Dr Reddys Laboratories Ltd. - Key offerings; Dr Reddys Laboratories Ltd. - Segment focus; 12.11 Eisai Co. Ltd.; Eisai Co. Ltd. - Overview; Eisai Co. Ltd. - Business segments; Eisai Co. Ltd. - Key offerings; Eisai Co. Ltd. - Segment focus; 12.12 Fresenius SE and Co. KGaA; Fresenius SE and Co. KGaA - Overview; Fresenius SE and Co. KGaA - Business segments; Fresenius SE and Co. KGaA - Key news; Fresenius SE and Co. KGaA - Key offerings; Fresenius SE and Co. KGaA - Segment focus; 12.13 GlaxoSmithKline Plc; GlaxoSmithKline Plc - Overview; GlaxoSmithKline Plc - Business segments; GlaxoSmithKline Plc - Key news; GlaxoSmithKline Plc - Key offerings; GlaxoSmithKline Plc - Segment focus; 12.14 inovapharma.com; inovapharma.com - Overview; inovapharma.com - Product / Service; inovapharma.com - Key offerings; 12.15 Johnson and Johnson Services Inc.; Johnson and Johnson Services Inc. - Overview; Johnson and Johnson Services Inc. - Business segments; Johnson and Johnson Services Inc. - Key news; Johnson and Johnson Services Inc. - Key offerings; Johnson and Johnson Services Inc. - Segment focus; 12.16 Lupin Ltd.; Lupin Ltd. - Overview; Lupin Ltd. - Product / Service; Lupin Ltd. - Key news; Lupin Ltd. - Key offerings; 12.17 Perrigo Co. Plc; Perrigo Co. Plc - Overview; Perrigo Co. Plc - Business segments; Perrigo Co. Plc - Key offerings; Perrigo Co. Plc - Segment focus
13 Appendix: 13.1 Scope of the report; 13.2 Inclusions and exclusions checklist; Inclusions checklist; Exclusions checklist; 13.3 Currency conversion rates for US$; Currency conversion rates for US$; 13.4 Research methodology; Research methodology; 13.5 Data procurement; Information sources; 13.6 Data validation; Data validation; 13.7 Validation techniques employed for market sizing; Validation techniques employed for market sizing; 13.8 Data synthesis; Data synthesis; 13.9 360 degree market analysis; 360 degree market analysis; 13.10 List of abbreviations; List of abbreviations
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Global Market Characteristics; Exhibits4: Executive Summary - Chart on Market by Geography; Exhibits5: Executive Summary - Chart on Market Segmentation by Route of Administration; Exhibits6: Executive Summary - Chart on Market Segmentation by Type; Exhibits7: Executive Summary - Chart on Incremental Growth; Exhibits8: Executive Summary - Data Table on Incremental Growth; Exhibits9: Executive Summary - Chart on Company Market Positioning; Exhibits10: Parent Market; Exhibits11: Data Table on - Parent Market; Exhibits12: Market characteristics analysis; Exhibits13: Value Chain Analysis; Exhibits14: Offerings of companies included in the market definition; Exhibits15: Market segments; Exhibits16: Chart on Global - Market size and forecast 2023-2028 ($ million); Exhibits17: Data Table on Global - Market size and forecast 2023-2028 ($ million); Exhibits18: Chart on Global Market: Year-over-year growth 2023-2028 (%); Exhibits19: Data Table on Global Market: Year-over-year growth 2023-2028 (%); Exhibits20: Historic Market Size - Data Table on Global Gastroesophageal Reflux Disease (GERD) Market 2018 - 2022 ($ million); Exhibits21: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million); Exhibits22: Historic Market Size - Type Segment 2018 - 2022 ($ million); Exhibits23: Historic Market Size - Geography Segment 2018 - 2022 ($ million); Exhibits24: Historic Market Size - Country Segment 2018 - 2022 ($ million); Exhibits25: Five forces analysis - Comparison between 2023 and 2028; Exhibits26: Bargaining power of buyers - Impact of key factors 2023 and 2028; Exhibits27: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; Exhibits28: Threat of new entrants - Impact of key factors in 2023 and 2028; Exhibits29: Threat of substitutes - Impact of key factors in 2023 and 2028; Exhibits30: Threat of rivalry - Impact of key factors in 2023 and 2028; Exhibits31: Chart on Market condition - Five forces 2023 and 2028; Exhibits32: Chart on Route of Administration - Market share 2023-2028 (%); Exhibits33: Data Table on Route of Administration - Market share 2023-2028 (%); Exhibits34: Chart on Comparison by Route of Administration; Exhibits35: Data Table on Comparison by Route of Administration; Exhibits36: Chart on Oral - Market size and forecast 2023-2028 ($ million); Exhibits37: Data Table on Oral - Market size and forecast 2023-2028 ($ million); Exhibits38: Chart on Oral - Year-over-year growth 2023-2028 (%); Exhibits39: Data Table on Oral - Year-over-year growth 2023-2028 (%); Exhibits40: Chart on Parenteral - Market size and forecast 2023-2028 ($ million); Exhibits41: Data Table on Parenteral - Market size and forecast 2023-2028 ($ million); Exhibits42: Chart on Parenteral - Year-over-year growth 2023-2028 (%); Exhibits43: Data Table on Parenteral - Year-over-year growth 2023-2028 (%); Exhibits44: Market opportunity by Route of Administration ($ million); Exhibits45: Data Table on Market opportunity by Route of Administration ($ million); Exhibits46: Chart on Type - Market share 2023-2028 (%); Exhibits47: Data Table on Type - Market share 2023-2028 (%); Exhibits48: Chart on Comparison by Type; Exhibits49: Data Table on Comparison by Type; Exhibits50: Chart on Antacid - Market size and forecast 2023-2028 ($ million); Exhibits51: Data Table on Antacid - Market size and forecast 2023-2028 ($ million); Exhibits52: Chart on Antacid - Year-over-year growth 2023-2028 (%); Exhibits53: Data Table on Antacid - Year-over-year growth 2023-2028 (%); Exhibits54: Chart on PPI - Market size and forecast 2023-2028 ($ million); Exhibits55: Data Table on PPI - Market size and forecast 2023-2028 ($ million); Exhibits56: Chart on PPI - Year-over-year growth 2023-2028 (%); Exhibits57: Data Table on PPI - Year-over-year growth 2023-2028 (%); Exhibits58: Chart on H2 receptor antagonist drugs - Market size and forecast 2023-2028 ($ million); Exhibits59: Data Table on H2 receptor antagonist drugs - Market size and forecast 2023-2028 ($ million); Exhibits60: Chart on H2 receptor antagonist drugs - Year-over-year growth 2023-2028 (%); Exhibits61: Data Table on H2 receptor antagonist drugs - Year-over-year growth 2023-2028 (%); Exhibits62: Chart on Prokinetic drugs - Market size and forecast 2023-2028 ($ million); Exhibits63: Data Table on Prokinetic drugs - Market size and forecast 2023-2028 ($ million); Exhibits64: Chart on Prokinetic drugs - Year-over-year growth 2023-2028 (%); Exhibits65: Data Table on Prokinetic drugs - Year-over-year growth 2023-2028 (%); Exhibits66: Market opportunity by Type ($ million); Exhibits67: Data Table on Market opportunity by Type ($ million); Exhibits68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits69: Chart on Market share By Geographical Landscape2023-2028 (%); Exhibits70: Data Table on Market share By Geographical Landscape2023-2028 (%); Exhibits71: Chart on Geographic comparison; Exhibits72: Data Table on Geographic comparison; Exhibits73: Chart on North America - Market size and forecast 2023-2028 ($ million); Exhibits74: Data Table on North America - Market size and forecast 2023-2028 ($ million); Exhibits75: Chart on North America - Year-over-year growth 2023-2028 (%); Exhibits76: Data Table on North America - Year-over-year growth 2023-2028 (%); Exhibits77: Chart on Europe - Market size and forecast 2023-2028 ($ million); Exhibits78: Data Table on Europe - Market size and forecast 2023-2028 ($ million); Exhibits79: Chart on Europe - Year-over-year growth 2023-2028 (%); Exhibits80: Data Table on Europe - Year-over-year growth 2023-2028 (%); Exhibits81: Chart on Asia - Market size and forecast 2023-2028 ($ million); Exhibits82: Data Table on Asia - Market size and forecast 2023-2028 ($ million); Exhibits83: Chart on Asia - Year-over-year growth 2023-2028 (%); Exhibits84: Data Table on Asia - Year-over-year growth 2023-2028 (%); Exhibits85: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Exhibits86: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Exhibits87: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits88: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits89: Chart on US - Market size and forecast 2023-2028 ($ million); Exhibits90: Data Table on US - Market size and forecast 2023-2028 ($ million); Exhibits91: Chart on US - Year-over-year growth 2023-2028 (%); Exhibits92: Data Table on US - Year-over-year growth 2023-2028 (%); Exhibits93: Chart on Germany - Market size and forecast 2023-2028 ($ million); Exhibits94: Data Table on Germany - Market size and forecast 2023-2028 ($ million); Exhibits95: Chart on Germany - Year-over-year growth 2023-2028 (%); Exhibits96: Data Table on Germany - Year-over-year growth 2023-2028 (%); Exhibits97: Chart on UK - Market size and forecast 2023-2028 ($ million); Exhibits98: Data Table on UK - Market size and forecast 2023-2028 ($ million); Exhibits99: Chart on UK - Year-over-year growth 2023-2028 (%); Exhibits100: Data Table on UK - Year-over-year growth 2023-2028 (%); Exhibits101: Chart on China - Market size and forecast 2023-2028 ($ million); Exhibits102: Data Table on China - Market size and forecast 2023-2028 ($ million); Exhibits103: Chart on China - Year-over-year growth 2023-2028 (%); Exhibits104: Data Table on China - Year-over-year growth 2023-2028 (%); Exhibits105: Chart on Canada - Market size and forecast 2023-2028 ($ million); Exhibits106: Data Table on Canada - Market size and forecast 2023-2028 ($ million); Exhibits107: Chart on Canada - Year-over-year growth 2023-2028 (%); Exhibits108: Data Table on Canada - Year-over-year growth 2023-2028 (%); Exhibits109: Market opportunity By Geographical Landscape($ million); Exhibits110: Data Tables on Market opportunity By Geographical Landscape($ million); Exhibits111: Impact of drivers and challenges in 2023 and 2028; Exhibits112: Overview on criticality of inputs and factors of differentiation; Exhibits113: Overview on factors of disruption; Exhibits114: Impact of key risks on business; Exhibits115: Companies covered; Exhibits116: Matrix on companies position and classification; Exhibits117: Abbott Laboratories - Overview; Exhibits118: Abbott Laboratories - Business segments; Exhibits119: Abbott Laboratories - Key news; Exhibits120: Abbott Laboratories - Key offerings; Exhibits121: Abbott Laboratories - Segment focus; Exhibits122: Alkem Laboratories Ltd. - Overview; Exhibits123: Alkem Laboratories Ltd. - Business segments; Exhibits124: Alkem Laboratories Ltd. - Key offerings; Exhibits125: Alkem Laboratories Ltd. - Segment focus; Exhibits126: Apotex Inc. - Overview; Exhibits127: Apotex Inc. - Product / Service; Exhibits128: Apotex Inc. - Key news; Exhibits129: Apotex Inc. - Key offerings; Exhibits130: AstraZeneca Plc - Overview; Exhibits131: AstraZeneca Plc - Product / Service; Exhibits132: AstraZeneca Plc - Key news; Exhibits133: AstraZeneca Plc - Key offerings; Exhibits134: Aurobindo Pharma Ltd. - Overview; Exhibits135: Aurobindo Pharma Ltd. - Product / Service; Exhibits136: Aurobindo Pharma Ltd. - Key offerings; Exhibits137: Bayer AG - Overview; Exhibits138: Bayer AG - Business segments; Exhibits139: Bayer AG - Key news; Exhibits140: Bayer AG - Key offerings; Exhibits141: Bayer AG - Segment focus; Exhibits142: Cipla Inc. - Overview; Exhibits143: Cipla Inc. - Business segments; Exhibits144: Cipla Inc. - Key news; Exhibits145: Cipla Inc. - Key offerings; Exhibits146: Cipla Inc. - Segment focus; Exhibits147: Dr Reddys Laboratories Ltd. - Overview; Exhibits148: Dr Reddys Laboratories Ltd. - Business segments; Exhibits149: Dr Reddys Laboratories Ltd. - Key news; Exhibits150: Dr Reddys Laboratories Ltd. - Key offerings; Exhibits151: Dr Reddys Laboratories Ltd. - Segment focus; Exhibits152: Eisai Co. Ltd. - Overview; Exhibits153: Eisai Co. Ltd. - Business segments; Exhibits154: Eisai Co. Ltd. - Key offerings; Exhibits155: Eisai Co. Ltd. - Segment focus; Exhibits156: Fresenius SE and Co. KGaA - Overview; Exhibits157: Fresenius SE and Co. KGaA - Business segments; Exhibits158: Fresenius SE and Co. KGaA - Key news; Exhibits159: Fresenius SE and Co. KGaA - Key offerings; Exhibits160: Fresenius SE and Co. KGaA - Segment focus; Exhibits161: GlaxoSmithKline Plc - Overview; Exhibits162: GlaxoSmithKline Plc - Business segments; Exhibits163: GlaxoSmithKline Plc - Key news; Exhibits164: GlaxoSmithKline Plc - Key offerings; Exhibits165: GlaxoSmithKline Plc - Segment focus; Exhibits166: inovapharma.com - Overview; Exhibits167: inovapharma.com - Product / Service; Exhibits168: inovapharma.com - Key offerings; Exhibits169: Johnson and Johnson Services Inc. - Overview; Exhibits170: Johnson and Johnson Services Inc. - Business segments; Exhibits171: Johnson and Johnson Services Inc. - Key news; Exhibits172: Johnson and Johnson Services Inc. - Key offerings; Exhibits173: Johnson and Johnson Services Inc. - Segment focus; Exhibits174: Lupin Ltd. - Overview; Exhibits175: Lupin Ltd. - Product / Service; Exhibits176: Lupin Ltd. - Key news; Exhibits177: Lupin Ltd. - Key offerings; Exhibits178: Perrigo Co. Plc - Overview; Exhibits179: Perrigo Co. Plc - Business segments; Exhibits180: Perrigo Co. Plc - Key offerings; Exhibits181: Perrigo Co. Plc - Segment focus; Exhibits182: Inclusions checklist; Exhibits183: Exclusions checklist; Exhibits184: Currency conversion rates for US$; Exhibits185: Research methodology; Exhibits186: Information sources; Exhibits187: Data validation; Exhibits188: Validation techniques employed for market sizing; Exhibits189: Data synthesis; Exhibits190: 360 degree market analysis; Exhibits191: List of abbreviations